Oncology

RET-altered thyroid cancer: how selective inhibitors changed advanced disease

The advent of selective RET inhibitors has significantly improved outcomes for patients with advanced RET-altered thyroid cancer. These targeted therapies address a critical unmet need in a previously challenging disease landscape.

Radioactive iodine: Which low-risk thyroid cancer patients can safely skip it?

For low-risk differentiated thyroid cancer, selective use of radioactive iodine ablation is a viable strategy, sparing many patients unnecessary treatment.

PD-L1 as a compass for immunotherapy in head and neck cancer

PD-L1 expression levels guide selection for immunotherapy in recurrent and metastatic head and neck squamous cell carcinoma, impacting treatment efficacy.

Managing the lasting damage of head and neck cancer treatment

Chemoradiation for head and neck cancers often leaves patients with chronic dysphagia and osteoradionecrosis, requiring complex, multidisciplinary management strategies.

De-escalation in HPV-positive oropharyngeal cancer: What trials have settled

Treatment de-escalation strategies for HPV-positive oropharyngeal cancer aim to reduce toxicity while maintaining efficacy, with ongoing trials exploring various approaches.

Why ovarian cancer is still diagnosed late, despite decades of screening research

Despite extensive research into screening methods, ovarian cancer continues to be diagnosed at advanced stages, limiting treatment efficacy.

Folate Receptor Alpha Testing: Why Timing Matters in Platinum-Resistant Ovarian Cancer

Folate receptor alpha expression in ovarian cancer can change over time, complicating treatment decisions for mirvetuximab soravtansine in platinum-resistant disease.

PARP Inhibitors in Ovarian Cancer: HRD Status Dictates Maintenance Benefit

PARP inhibitors have transformed ovarian cancer treatment, but homologous recombination deficiency status critically determines their long-term efficacy.

HPV-driven oropharyngeal cancer: When smoking complicates a 'good' prognosis

HPV-associated oropharyngeal squamous cell carcinoma carries a better prognosis than HPV-negative disease, but smoking history significantly worsens outcomes, complicating de-escalation strategies.